Curaxis Pharmaceutical Corp. is an emerging specialty pharmaceutical company. They have a pipeline of product candidates in Alzheimer’s disease and oncology. The Company bases their therapeutic platform on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. Founded in 2001, Curaxis Pharmaceutical Corp. has their headquarters in Swampscott, Massachusetts.
The HPG axis is a hormonal endocrine feedback loop. It controls development, reproduction and aging in animals. The building of this drug development platform is on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development. However, they are harmful later in life when the mechanism for feedback is compromised. Consequently, this leads to disease processes, such as pathologies associated with Alzheimer’s disease and various cancers.
Curaxis Pharmaceutical Corp. believes their discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer’s patients and in multiple tumors will enable them to develop major new treatments for Alzheimer’s disease and numerous cancers.
The Company’s most advanced product candidate is Memryte (generic name VP4896). This proprietary, small, biodegradable implant consists of leuprolide acetate and a polymer. Memryte is a patented treatment, which has shown the potential for treating and halting the progression of Alzheimer’s Disease (AD).
Curaxis Pharmaceutical’s clinical programs include ALADDIN I/103, which completed Phase II clinical trial for the treatment of women aged 65 years or older with mild to moderate Alzheimer’s disease. They also include ALADDIN II/104, which completed Phase II clinical trial for the treatment of men aged 65 years or older with mild to moderate Alzheimer’s disease. Additionally, they include ALADDIN 105 that completed Phase I clinical trial for healthy women aged 45 to 70 years and men aged 50 to 70 years.
In May, Curaxis Pharmaceutical Corp. announced that the Company’s lead drug hormone product for Alzheimer’s disease, Memryte, was named by the editors of R&D Directions magazine as one of the top “100 Great Investigational Drugs in Development” today. In their tenth annual list of promising clinical compounds, R&D Directions cited this Curaxis drug, which addresses the pathologies of Alzheimer’s disease via multiple pathways. These include beta amyloid, tau phosphorylation, inflammation and aberrant cell cycling, as a unique clinical approach in targeting the brain disorder.